September 17, 2025
A rate decision outcome, but what’s coming next, the Q is coming to a close and as I have written, the cell and gene therapy sector investors are existing in a “catalyst vacuum”?
Pre-Open Signals: 4 Positive, 1 Sell into Strength and 1 Negative indications
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
September 15, 2025
Roche (RHO-DE: XETRA) confirmed it is staying put for now after fallout from drug pricing negotiations that saw the nation’s health minister walk away from talks.
Merck (MRK) is moving all R&D operations out of UK,
Eli Lilly (LLY) is pausing the build-out of UK biotech incubator,
September 17, 2025
The cell and gene therapy sector responded in its usual alternating downtrend as I have written “econs have been poison” to our universe
Again, investors felt pain, “riding the skids of uncle algo and his electronic trading dwarfs” by the cell and gene therapy sector’s being sold through
Never leave an investor uninformed!
September 15, 2025
Roche (RHO-DE: XETRA) confirmed it is staying put for now after fallout from drug pricing negotiations that saw the nation’s health minister walk away from talks. Merck (MRK) is moving all R&D operations out of UK, Eli Lilly (LLY) is pausing the build-out of UK biotech incubator,
September 2, 2025
A net loss of -$18.23 M or -$0.11 per share, revenue of $317 K <cost of sales = $302 K>, a cash position of $786 K <liabilities -$1.376 M>, with a runway until Q3/25. What happened and where is the $2 M "Exempt Offering of Securities" Trouble in offering land? Accumulated deficit to date= $103.2 M U.S. investors BEWARE, forewarned is forearmed?
August 28, 2025
Stay with me … Who is speaking-up for investors? I write this blog/newsletter about – facts in evidence! I will still answer or qualify the sector’s equity’s share pricing mobility; with an emphasis on which company is gaining or losing stride in your portfolio in the short and near-term I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
